Who are Replacement with Zonisamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): zonisamide high dose group, Standard dose zonisamide, Oral Zonisamide Therapy, Adjunctive Zonisamide, Low dose zonisamide, Placebo ZNS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/replacement-with-zonisamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Replacement with Zonisamide — Competitive Intelligence Brief

Replacement with Zonisamide (Replacement with Zonisamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic drug. Area: Neurology.

marketed Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels, T-type calcium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Replacement with Zonisamide (Replacement with Zonisamide) — Eisai Inc.. Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Replacement with Zonisamide TARGET	Replacement with Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels
zonisamide high dose group	zonisamide high dose group	Eisai Korea Inc.	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA enhancement
Standard dose zonisamide	Standard dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA signaling
Oral Zonisamide Therapy	Oral Zonisamide Therapy	Affiliated Hospital of Nantong University	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Adjunctive Zonisamide	Adjunctive Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Placebo ZNS	Placebo ZNS	Impax Laboratories, LLC	phase 3	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic drug class)

Mario Negri Institute for Pharmacological Research · 3 drugs in this class
Eisai Inc. · 2 drugs in this class
Affiliated Hospital of Nantong University · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
MaineHealth · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Replacement with Zonisamide — Competitive Intelligence Brief. https://druglandscape.com/ci/replacement-with-zonisamide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab